Mitra, Akash http://orcid.org/0000-0002-0633-1615
Andrews, Miles C. http://orcid.org/0000-0003-1231-8641
Roh, Whijae http://orcid.org/0000-0002-7395-9939
De Macedo, Marianna Petaccia http://orcid.org/0000-0002-0434-7605
Hudgens, Courtney W. http://orcid.org/0000-0001-8312-7485
Carapeto, Fernando
Singh, Shailbala
Reuben, Alexandre http://orcid.org/0000-0003-4510-0382
Wang, Feng
Mao, Xizeng
Song, Xingzhi
Wani, Khalida
Tippen, Samantha
Ng, Kwok-Shing http://orcid.org/0000-0003-0364-7443
Schalck, Aislyn
Sakellariou-Thompson, Donald A.
Chen, Eveline
Reddy, Sangeetha M.
Spencer, Christine N.
Wiesnoski, Diana
Little, Latasha D.
Gumbs, Curtis
Cooper, Zachary A. http://orcid.org/0000-0003-1059-0940
Burton, Elizabeth M.
Hwu, Patrick
Davies, Michael A. http://orcid.org/0000-0002-0977-0912
Zhang, Jianhua http://orcid.org/0000-0001-5412-9860
Bernatchez, Chantale
Navin, Nicholas
Sharma, Padmanee
Allison, James P.
Wargo, Jennifer A. http://orcid.org/0000-0003-3438-7576
Yee, Cassian
Tetzlaff, Michael T.
Hwu, Wen-Jen
Lazar, Alexander J. http://orcid.org/0000-0002-6395-4499
Futreal, P. Andrew http://orcid.org/0000-0001-8663-2671
Article History
Received: 17 June 2019
Accepted: 11 March 2020
First Online: 15 April 2020
Competing interests
: The authors declare the following competing interests: M.C.A. reports advisory board participation and honoraria from Merck Sharp and Dohme, outside the submitted work. Z.A.C. is currently an employee of Medimmune. D.W. is currently an employee of Vedanta Biosciences. CNS is currently an employee of Parker Institute for Cancer Immunotherapy. A.J.L. reports personal fees from Merck, Bristol-Myers Squibb, Novartis, and Roche/Genentech; personal fees and non-financial support from ArcherDX and Beta-Cat; grants and non-financial support from Medimmune/AstraZeneca and Sanofi; and grants, personal fees, and non-financial support from Janssen, all outside the submitted work. P.H. reports consultant or advisor fees from Dragonfly Therapeutics, GlaxoSmithKline, Immatics, and Sanofi. P.S. reports consultant or advisor fees from Bristol-Myers Squibb, GlaxoSmithKline, AstraZeneca, Amgen, Jounce, Kite Pharma, Neon, Evelo, EMD Serono, and Astellas; stock from Jounce, Kite Pharma, Evelo, Constellation, Neon; and has a patent licensed to Jounce, all outside the submitted work. J.P.A. reports stock ownership from Jounce, Neon, BioAtla, Forty-Seven, Apricity, Polaris, Marker Therapeutics, Codiak, Kite Pharma, and consultant or advisor fees from Jounce, Neon, Amgen, Forty-Seven, Apricity, Polaris, Marker Therapeutics, Codiak, BioAlta LLC, Tvardi Therapeutics, and owns patents licensed to Jounce, Merck & BMS. M.T.T. reports personal fees from Myriad Genetics, Seattle Genetics and Novartis LLC, all outside the submitted work. C.N.S., A.R., and J.A.W. are co-inventors on US patent (PCT/US17/53.717) relating to the microbiome, outside of the current work. J.A.W. reports speaker fees from Imedex, Dava Oncology, Omniprex, Illumina, Gilead, MedImmune, and Bristol-Myers Squibb; consultant/advisor roles or advisory board membership for Roche-Genentech, Novartis, AstraZeneca, GlaxoSmithKline, Bristol-Myers Squibb, Merck/MSD, Biothera Pharma, and Microbiome DX; and receives clinical trial support from GlaxoSmithKline, Roche/Genentech, Bristol-Myers Squibb, and Novartis, all outside the current work. M.A.D. reports being the PI of research supported by grants to his institution from Myriad, AstraZeneca, Roche/Genentech, GlaxoSmithKline, Oncothyreon, and Sanofi-Aventis; consulting for NanoString; and advisory board participation for GlaxoSmithKline, Roche/Genentech, Novartis, Array, Bristol-Myers Squibb, Sanofi-Aventis, and Vaccinex. W.J.H. reports research support from Merck, Schering-Plough, GlaxoSmithKline, Bristol-Myers Squibb, and MedImmune, outside the current work. P.A.F. reports consulting for Gene+, outside of the current work. All other authors declare no competing interests.